Experimental cancer drug that targets common genetic fault can shrink tumours by 64% in six weeks

The drug AMG 510 was tested on four lung cancer patients. Two patients saw their tumours reduce, according to the pharmaceutical giant Amgen Research, California.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news